Navigation Links
RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
Date:12/12/2008

y and through its influence on two of the most important pathways for breast cancer, the erbB receptor and the HER2 pathways.

"We are encouraged by the benefit RAD001 provided to advanced breast cancer patients in these early trials," said Alessandro Riva, MD, Executive Vice President & Global Head of Development, Novartis Oncology. "Novartis is committed to further evaluating the potential of RAD001 in combination with Herceptin as a new treatment regimen in breast cancer, as well as studying its role in treating other tumor types."

Novartis will initiate a worldwide Phase III clinical trial program to further evaluate the potential of RAD001 in combination with Herceptin and chemotherapy in patients with HER2-positive metastatic breast cancer. To learn more about the trial, please visit http://mail.breastcancerresearchstudy.com/, or speak to your doctor.

Study details: abstract #3119

An open-label, multicenter Phase I dose escalation trial evaluated daily RAD001 (5 mg, 10 mg) and weekly RAD001 (30 mg, 50 mg and 70 mg) regimens in combination with Taxol (80 mg/m2 IV over 60 min on days 1, 8 and 15 every 28 days) and Herceptin (2 mg/kg IV over 30 min) in heavily pretreated patients with HER2-positive metastatic breast cancer with prior resistance to Herceptin.

Across treatment arms, there was an overall disease control rate of 77% (complete response/ partial response/ stable disease greater than or equal to 16 weeks). Twenty-two heavily pretreated patients were evaluable for efficacy: treatment arms included five patients assigned to RAD001 5 mg daily, eight to RAD001 10 mg daily and nine to RAD001 30 mg weekly. Among the five patients evaluated in the 5 mg daily treatment arm, one patient had a complete response and four patients had partial responses. In the 10 mg daily treatment arm, one patient had
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
2. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
3. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
4. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
5. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
6. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
7. New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
8. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
9. Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
10. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
11. Soft Contact Lenses Do Not Lead to Myopic Creep in Children, Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014 A victim of medical negligence at ... doctor with a history of alcohol abuse, a physician and ... Prop 46 today, highlighting how Prop 46 will identify and ... The ad pictures a doctor drinking at ... ER."  Proposition 46 will enact the first law in the ...
(Date:10/17/2014)... , Oct. 17, 2014  UBM Medica US announces ... for endocrinologists and other clinicians who treat patients with ... on effective use of insulin .  ... insulin replacement therapy – daily injections of ... progressive decline in the function of pancreatic beta cells. ...
(Date:10/17/2014)... ANDOVER, Mass. , Oct. 17, 2014   ... pulmonary function testing (PFT) employing precise ultrasound technology, announced ... the Choctaw Nation Healthcare Center , a 140,000 ... Talihina, Oklahoma hospital serves a ... in southeastern Oklahoma and beyond. ...
Breaking Medicine Technology:Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
... CyberKnife Coalition announced today that more than ... have now been enrolled in the first national patient ... treated with stereotactic body radiation therapy. The multi-institutional ... functional outcomes of men with localized prostate cancer treated ...
... 30, 2011   Takeda ... completed its acquisition of Nycomed A/S ("Nycomed") for 9.6 ... Nycomed a wholly owned subsidiary of Takeda effective the ... of Nycomed in addition to his current role as ...
Cached Medicine Technology:First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2Takeda Completes Acquisition and Names New CEO of Nycomed 2Takeda Completes Acquisition and Names New CEO of Nycomed 3Takeda Completes Acquisition and Names New CEO of Nycomed 4
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... CO (PRWEB) October 20, 2014 ... assays are the only imaging assays capable of ... a single test.  With these three dimensions of ... ability to detect the widest range of disease-causing ... usually missed by other genomic tools, including today’s ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Feb. 18, 2008 Seattle Childrens Hospital Research Institute announced ... the Bill & Melinda Gates Foundation to study ways to ... over 1 million newborn babies worldwide each year. It ... States with over 10,000 babies dying each year. Over 3 ...
... remarks by President Bush., Meru District Hospital ... zenu. We have just toured the hospital here,which is on ... Doc, for leading the tour, and for your compassion. I ... to thank Minister,Mwakyusa for joining us here in Arusha. I,m ...
... other cells what to do, but new evidence suggests that, ... much to contribute, scientists say. , In an animal model, ... muscle cell fails to produce the protein beta-catenin, its neuron ... of the first proof that in vertebrates such as man, ...
... a variety of potentially toxic agents during pregnancy remains ... in society at large. However, there is now ... fetal and postnatal development of offspring and that this ... multidisciplinary symposium, sponsored by the American Association for the ...
... But many patients aren,t getting the lifesaving treatment, research ... clear that chemotherapy after breast cancer surgery increases survival ... potentially lifesaving treatment. , But, age shouldn,t be a ... to be a better predictor of positive results after ...
... A mathematical model that looks at different strategies ... and patient isolation may be effective approaches when ... era of superbugs, such as methicillin-resistant Staphylococcus aureas ... over bacterial infections, this type of modeling, if ...
Cached Medicine News:Health News:Researchers aim to prevent global prematurity and stillbirths 2Health News:Researchers aim to prevent global prematurity and stillbirths 3Health News:Remarks by President Bush on Malaria 2Health News:Remarks by President Bush on Malaria 3Health News:2-way cell talk provides clues about neuromuscular disease 2Health News:Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too 2Health News:Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too 3Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: